Find Setmelanotide Acetate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 920014-72-8, Rm-493, Bim-22493, Setmelanotide acetate, N7t15v1fuy, (4r,7s,10s,13r,16s,19r,22r)-22-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1h-imidazol-5-ylmethyl)-7-(1h-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide
Molecular Formula
C49H68N18O9S2
Molecular Weight
1117.3  g/mol
InChI Key
HDHDTKMUACZDAA-PHNIDTBTSA-N
FDA UNII
N7T15V1FUY

Setmelanotide Acetate
Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. It is an agonist of the melanocortin 4 receptor. Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. Other earlier treatments for these patients included gastric bypass surgery. Patients taking setmelanotide experienced an average weight loss of 0.6 kg/week. Imcivree was granted EMA orphan designation on 19 November 2018 and FDA approval on 25 November 2020.
Setmelanotide is a Melanocortin 4 Receptor Agonist. The mechanism of action of setmelanotide is as a Melanocortin 4 Receptor Agonist.
1 2D Structure

Setmelanotide Acetate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide
2.1.2 InChI
InChI=1S/C49H68N18O9S2/c1-26-41(70)63-37(20-30-22-55-25-59-30)46(75)64-35(18-28-10-4-3-5-11-28)44(73)62-34(15-9-17-57-49(53)54)43(72)65-36(19-29-21-58-32-13-7-6-12-31(29)32)45(74)66-38(40(50)69)23-77-78-24-39(47(76)60-26)67-42(71)33(61-27(2)68)14-8-16-56-48(51)52/h3-7,10-13,21-22,25-26,33-39,58H,8-9,14-20,23-24H2,1-2H3,(H2,50,69)(H,55,59)(H,60,76)(H,61,68)(H,62,73)(H,63,70)(H,64,75)(H,65,72)(H,66,74)(H,67,71)(H4,51,52,56)(H4,53,54,57)/t26-,33+,34+,35-,36+,37+,38+,39+/m1/s1
2.1.3 InChI Key
HDHDTKMUACZDAA-PHNIDTBTSA-N
2.1.4 Canonical SMILES
CC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)N1)NC(=O)C(CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
2.1.5 Isomeric SMILES
C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
2.2 Other Identifiers
2.2.1 UNII
N7T15V1FUY
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Bim-22493

2. Imcivree

3. Rm-493

2.3.2 Depositor-Supplied Synonyms

1. 920014-72-8

2. Rm-493

3. Bim-22493

4. Setmelanotide Acetate

5. N7t15v1fuy

6. (4r,7s,10s,13r,16s,19r,22r)-22-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1h-imidazol-5-ylmethyl)-7-(1h-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide

7. 1504602-49-6

8. L-cysteinamide, N2-acetyl-l-arginyl-l-cysteinyl-d-alanyl-l-histidyl-d-phenylalanyl-l-arginyl-l-tryptophyl-, Cyclic (2->8)-disulfide

9. Unii-n7t15v1fuy

10. Setmelanotide [usan:inn]

11. Setmelanotide [usan]

12. Setmelanotide (rm-493)

13. Setmelanotide [inn]

14. Setmelanotide [who-dd]

15. Gtpl9272

16. Chembl3301624

17. Schembl21840385

18. Ex-a5542

19. At23144

20. Cs-6399

21. Db11700

22. Irc-022493

23. Hy-19870

24. Q21098917

25. Rm-493; Bim-22493; Irc-022493

26. N2-acetyl-l-arginyl-l-cysteinyl-d-alanyl-l-histidyl-d-phenylalanyl-l-arginyl-l-tryptophyl-l-cysteinamide, Cyclic (2-8)-disulfide

2.4 Create Date
2007-02-05
3 Chemical and Physical Properties
Molecular Weight 1117.3 g/mol
Molecular Formula C49H68N18O9S2
XLogP3-2.5
Hydrogen Bond Donor Count15
Hydrogen Bond Acceptor Count14
Rotatable Bond Count18
Exact Mass1116.48580817 g/mol
Monoisotopic Mass1116.48580817 g/mol
Topological Polar Surface Area500 Ų
Heavy Atom Count78
Formal Charge0
Complexity2130
Isotope Atom Count0
Defined Atom Stereocenter Count8
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Setmelanotide is indicated for chronic weight management in patients 6 years and older with obesity due to pro-opiomelanocortin deficiency, proprotein subtilisin/kexin type 1 deficiency, or leptin receptor deficiency. These conditions affect the MC4R signalling pathway.


Imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above.


Treatment of appetite and general nutrition disorders


5 Pharmacology and Biochemistry
5.1 Pharmacology

Setmelanotide agonizes MC4R, downstream of multiple potential genetic deficiencies, to induce a feeling of satiety for chronic weight management. It has a moderate duration of action as it is given daily. Patients should be counselled regarding the risk of disturbances in sexual arousal, depression and suicidal ideation, and darkening of skin pigmentation. Exercise caution in neonates and low birth weight infants, as they may experience serious adverse effects due to benzyl alcohol.


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
SETMELANOTIDE
5.2.2 FDA UNII
N7T15V1FUY
5.2.3 Pharmacological Classes
Melanocortin 4 Receptor Agonists [MoA]; Melanocortin 4 Receptor Agonist [EPC]
5.3 ATC Code

A08AA


A - Alimentary tract and metabolism

A08 - Antiobesity preparations, excl. diet products

A08A - Antiobesity preparations, excl. diet products

A08AA - Centrally acting antiobesity products

A08AA12 - Setmelanotide


5.4 Absorption, Distribution and Excretion

Absorption

Setmelanotide has a Tmax of 8 hours.


Route of Elimination

A 3mg subcutaneous dose of setmelanotide is 39% eliminated in the urine as the unchanged parent compound.


Volume of Distribution

The apparent volume of distribution of setmelanotide is 48.7 L.


Clearance

A 3mg subcutaneous dose of setmelanotide has an estimated clearance of 4.86 L/h.


5.5 Metabolism/Metabolites

Setmelanotide is expected to be metabolized to small peptides and amino acids.


5.6 Biological Half-Life

The elimination had life of setmelanotide is approximately 11 hours.


5.7 Mechanism of Action

Grehlin and other hunger signals from the gastrointestinal tract stimulate orexigenic neurons, stimulating the release of agouti-related protein. Agouti-related protein inhibits melanocortin 4 receptor (MC4R) activation until satiety signals such as insulin or leptin stimulate anorexigenic neurons. Insulin and leptin stimulate production of the POMC-derived melanocortin peptide -melanocyte simulating hormone, which is a ligand of MC4R. Orexigenic and anorexigenic neurons contain prohormone convertase 1/3 (PC1/3), which is encoded by the gene proprotein subtilisin/kexin type 1. PC1/3 preforms activation cleavage of a number of peptide hormone precursors, including -melanocyte simulating hormone. Setmelanotide is a pro-opiomelanocortin derived peptide that is an agonist of MC4R. It is an approximately 20-fold more potent agonist of MC4R than endogenous -melanocyte stimulating hormone, with an EC50 of 0.27 nM. By directly agonizing MC4R, upstream genetic deficiencies in the MC4R signalling pathway cannot inhibit satiety, food intake is decreased, and weight loss is achieved. MC4R is a 332 amino acid G-protein coupled receptor (G-PCR). Although the lack of cardiovascular adverse effects with setmelanotide treatment are not well understood, it is believed that earlier MC4R antagonists activated multiple G-protein signalling pathways. Earlier drugs that targeted G-PCRs either bound with high affinity to the highly conserved orthosteric binding site, or with high specificity to less conserved allosteric sites. Setmelanotide is an atypical bitopic ligand that interacts with both the orthosteric and putative allosteric binding site, allowing for both high affinity and specificity.


API SUPPLIERS

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Setmelanotide Acetate Manufacturers

A Setmelanotide Acetate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Setmelanotide Acetate, including repackagers and relabelers. The FDA regulates Setmelanotide Acetate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Setmelanotide Acetate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Setmelanotide Acetate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Setmelanotide Acetate Suppliers

A Setmelanotide Acetate supplier is an individual or a company that provides Setmelanotide Acetate active pharmaceutical ingredient (API) or Setmelanotide Acetate finished formulations upon request. The Setmelanotide Acetate suppliers may include Setmelanotide Acetate API manufacturers, exporters, distributors and traders.

click here to find a list of Setmelanotide Acetate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Setmelanotide Acetate NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Setmelanotide Acetate as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Setmelanotide Acetate API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Setmelanotide Acetate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Setmelanotide Acetate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Setmelanotide Acetate NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Setmelanotide Acetate suppliers with NDC on PharmaCompass.

Setmelanotide Acetate GMP

Setmelanotide Acetate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Setmelanotide Acetate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Setmelanotide Acetate GMP manufacturer or Setmelanotide Acetate GMP API supplier for your needs.

Setmelanotide Acetate CoA

A Setmelanotide Acetate CoA (Certificate of Analysis) is a formal document that attests to Setmelanotide Acetate's compliance with Setmelanotide Acetate specifications and serves as a tool for batch-level quality control.

Setmelanotide Acetate CoA mostly includes findings from lab analyses of a specific batch. For each Setmelanotide Acetate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Setmelanotide Acetate may be tested according to a variety of international standards, such as European Pharmacopoeia (Setmelanotide Acetate EP), Setmelanotide Acetate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Setmelanotide Acetate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty